Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1.

Derlin T, Tornquist K, Münster S, Apostolova I, Hagel C, Friedrich RE, Wedegärtner U, Mautner VF.

Clin Nucl Med. 2013 Jan;38(1):e19-25. doi: 10.1097/RLU.0b013e318266ce84.

PMID:
23242059
2.

Evaluation of intratumoural heterogeneity on ¹⁸F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1.

Salamon J, Derlin T, Bannas P, Busch JD, Herrmann J, Bockhorn M, Hagel C, Friedrich RE, Adam G, Mautner VF.

Eur J Nucl Med Mol Imaging. 2013 May;40(5):685-92. doi: 10.1007/s00259-012-2314-6. Epub 2012 Dec 12.

PMID:
23232507
3.
4.
5.

[18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.

Warbey VS, Ferner RE, Dunn JT, Calonje E, O'Doherty MJ.

Eur J Nucl Med Mol Imaging. 2009 May;36(5):751-7. doi: 10.1007/s00259-008-1038-0. Epub 2009 Jan 14.

PMID:
19142634
6.

18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.

Salamon J, Veldhoen S, Apostolova I, Bannas P, Yamamura J, Herrmann J, Friedrich RE, Adam G, Mautner VF, Derlin T.

Eur Radiol. 2014 Feb;24(2):405-12. doi: 10.1007/s00330-013-3020-x. Epub 2013 Oct 5.

PMID:
24097302
7.

Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion.

Urban T, Lim R, Merker VL, Muzikansky A, Harris GJ, Kassarjian A, Bredella MA, Plotkin SR.

Clin Nucl Med. 2014 May;39(5):e301-7. doi: 10.1097/RLU.0b013e3182a757d3.

PMID:
24152623
8.

Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.

Salamon J, Mautner VF, Adam G, Derlin T.

Rofo. 2015 Dec;187(12):1084-92. doi: 10.1055/s-0035-1553505. Epub 2015 Sep 2. Review.

9.

Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.

Karabatsou K, Kiehl TR, Wilson DM, Hendler A, Guha A.

Neurosurgery. 2009 Oct;65(4 Suppl):A160-70. doi: 10.1227/01.NEU.0000337597.18599.D3.

PMID:
19927062
10.

Foreign Body Abscess Mimicking a Malignant Peripheral Nerve Sheath Tumor in a Patient With Neurofibromatosis Type 1.

Salamon J, Hagel C, Friedrich RE, Mautner VF, Derlin T.

Clin Nucl Med. 2015 Aug;40(8):674-5. doi: 10.1097/RLU.0000000000000824.

PMID:
26018702
11.

Nerve Sheath Tumors in Neurofibromatosis Type 1: Assessment of Whole-Body Metabolic Tumor Burden Using F-18-FDG PET/CT.

Salamon J, Papp L, Tóth Z, Laqmani A, Apostolova I, Adam G, Mautner VF, Derlin T.

PLoS One. 2015 Dec 1;10(12):e0143305. doi: 10.1371/journal.pone.0143305. eCollection 2015.

12.

Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.

Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, Phelps ME, Weber WA, Eilber FC.

Cancer. 2010 Jan 15;116(2):451-8. doi: 10.1002/cncr.24755. Erratum in: Cancer. 2010 Feb 1;116(3):775.

13.

Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.

Eiber M, Takei T, Souvatzoglou M, Mayerhoefer ME, Fürst S, Gaertner FC, Loeffelbein DJ, Rummeny EJ, Ziegler SI, Schwaiger M, Beer AJ.

J Nucl Med. 2014 Feb;55(2):191-7. doi: 10.2967/jnumed.113.123646. Epub 2013 Dec 5.

14.
15.
16.

Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients.

Brahmi M, Thiesse P, Ranchere D, Mognetti T, Pinson S, Renard C, Decouvelaere AV, Blay JY, Combemale P.

PLoS One. 2015 Oct 7;10(10):e0138386. doi: 10.1371/journal.pone.0138386. eCollection 2015.

17.

Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.

Klenk C, Gawande R, Uslu L, Khurana A, Qiu D, Quon A, Donig J, Rosenberg J, Luna-Fineman S, Moseley M, Daldrup-Link HE.

Lancet Oncol. 2014 Mar;15(3):275-85. doi: 10.1016/S1470-2045(14)70021-X. Epub 2014 Feb 19.

PMID:
24559803
19.

Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.

Pace L, Nicolai E, Luongo A, Aiello M, Catalano OA, Soricelli A, Salvatore M.

Eur J Radiol. 2014 Feb;83(2):289-96. doi: 10.1016/j.ejrad.2013.11.002. Epub 2013 Nov 23.

PMID:
24331845
20.

Plurifocal malignant peripheral nerve sheath tumor demonstrated by 18F-fluorodeoxyglucose positron emission tomography/computed tomography.

Bertagna F, Bosio G, Biasiotto G, Savelli G, Rodella C, Giubbini R, Rosenbaum J, Alavi A.

Jpn J Radiol. 2009 Oct;27(8):320-3. doi: 10.1007/s11604-009-0343-2. Epub 2009 Oct 27.

PMID:
19856228

Supplemental Content

Support Center